Lynk Pharmaceuticals Completes Phase III AS Trial Enrollment
HANGZHOU, China, SHANGHAI & BOSTON — July 14, 2026 Lynk Pharmaceuticals Co., Ltd. has announced the successful completion of...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HANGZHOU, China, SHANGHAI & BOSTON — July 14, 2026 Lynk Pharmaceuticals Co., Ltd. has announced the successful completion of...
Los Angeles, California, USA, April 1, 2026 Partillion Bioscience has highlighted a transformative shift in modern biological research following...
Shanghai, China, July 1, 2026 Junshi Biosciences has entered into a landmark licensing collaboration with Fosun Wanbang Pharma Group,...
Basel, Switzerland, July 2, 2026 Novartis has achieved a major milestone in the treatment of spinal muscular atrophy (SMA)...
HONG KONG, June 11, 2026 Akeso, Inc. announced that China’s National Medical Products Administration (NMPA) has approved gumokimab (AK111,...
